AAPA: SCOTUS Mifepristone Ruling Protects PAs’ Prescribing Rights

June 13, 2024

The American Academy of Physician Associates (AAPA), released the following statement, on the Supreme Court of the United States’ (SCOTUS) decision to overturn a Fifth Circuit ruling that placed restrictions on mifepristone, including stripping away PA prescribing rights.

“Today’s decision from SCOTUS preserves patient access to mifepristone, a medication with a long history of safe and effective use,” AAPA President and Chair of the Board Folusho E. Ogunfiditimi, DM, MPH, PA-C, DFAAPA, said. “This is a win for science and ensures medical decisions remain in the hands of patients and their healthcare providers, not the courts.”

In February, AAPA along with the Association of PAs in Obstetrics and Gynecology (APAOG), the American College of Nurse Midwives (ACNW), and the National Association of Nurse Practitioners in Women’s Health (NPWH), submitted an amicus brief to SCOTUS, which challenged the Fifth’s Circuit’s finding that PAs could not be qualified prescribers of mifepristone.

The Food and Drug Administration cited the brief in its reply to the SCOTUS decision.